

Clinical benefit and cost evaluation of erythrocytapheresis compared to manual exchange transfusion for children with sickle cell disease: a single center experience

L. Dedeken, P.Q. Lê, L. Rozen, H. El Kenz, S. Huybrechts, C. Devalck, S. Diallo, C. Heijmans, A. Ferster

Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium




WAA/SFH Joint Congress, Paris, April 27-29, 2016



Introduction

- Chronic transfusion in Sickle Cell Disease
 - Primary and secondary stroke prevention



Continued transfusion 0.90 0.80 0.70 0.60 0.50 No continued transfusion 0.40 0.30 0.20 0.10 0.00 12 18 24 30 36 42 4 No. at Ris Continued tran fusion No continue transfusie Figure 2, Kaplan-Meier Estimates of the Probability of No End-Point Event among Patients Assigned to Continued Transfusion or No Continued Transfus P values were determined by the log-rank test

Adams et al, Control Clin Trials 1998

Pegelow et al, J Pediatr 1995

STOP 2, NEJM 2005

Recurrent vaso-occlusive crisis or acute chest syndrome despite hydroxyurea

With Transfusio

Time to Second

- Prevention of progressive organ damage

Hôpital Universitaire des Enfants Reine Fabiola Universitair Kinderziekenhuis Kohindin Tabiola



Simple transfusion vs. exchange transfusion?

TOP-UP		EXCHANGE		
+	-	+	-	
HbS dilution	Increased viscosity	Rapid decrease in HbS	Venous access	
Restauration of blood volume and hematocrit		No increase in the viscosity	Large amount of RBC, Higher risk of	
Venous access	Iron overload		alloimmunization	
Few RBC		\downarrow Iron overload	Equipment, expertise, cost, time-consuming	
Hôpital Universitaire des Enfants Reine Fabiola Universitair Kinderziekenhuis			UNIVERS LIBRE	

Kohindin Tabiola

DE BRUXELLES

Aim of the study

- To assess the safety and efficacy of erythrocytapheresis (ECP) in SCD patients previously treated with manual exchange transfusion (MET)
- To evaluate the changes of the cost over the years





Material & Methods

- Eyrthrocytapheresis (ECP)
 - From January 2012
 - 10 patients shifted from MET to ECP
 - ≥ 30 kg and sufficient peripheral venous access
- Spectra Optia® Apheresis System
- Peripheral venous access
- Standardized prescriptions
 - 1.5 x red cell volumes
 - IV calcium supplements





- Data were recorded for the last 6 months on MET and compared to the data of the 1st and 2nd year on ECP
- Cost evaluation
 - The overall cost of last year on MET, 1st year and 2nd year on ECP were analyzed (packed RBCs, one-day care facility and chelation)
- Friedman test was used to compare the treatment over the years and Dunn's Multiple Comparison Test used to compare yearly treatment
- Target HbS was < 30% in case of stroke and < 50% for other indications





Results





Characterisitcs of the patients

Number of patients	10		
Sex (M)	8		
Age at switch (median, range)	11.8y (9.6-16.8)		
Duration of MET before ECP (median, range)	1.9y (0.5-4.4)		
Duration of ECP after switch	2у		
Number of ECP (median, range)	21 (19-27)		





Indications of Chronic Transfusion Program


Number of patients	10
Primary stroke prevention	0
Secondary stroke prevention	2
Recurrent VOC-ACS	5
Pulmonary hypertension	2
Untolerated severe anemia*	1






Biological data

				Р			
N = 10		1st Year			2 nd Year		
	Median	Range	Median	Range	Median	Range	
Hb (g/l)	9,95	8,6-10,8	9,93	8,85-10,6	9,7	9,1-11,7	NS
Hb S (%)	33,5	25-42	39,3	29-42	45	32-49	***
Ferritin (µg/l)	663,3	182-1512	257	52,5-811	126,8	8-622	***











Universitair Kinderziekenhuis Koningin Tabiola

Time saving

			On ECP				
N = 10	O	On MET		1 st year		2 nd year	
	Median	Range	Median	Range	Median	Range	
Procedure duration	266.3	195.0-385.0	86.0	76.0-124.5	90.0	65.0-154.0	**
(min)	200.5	193.0-303.0	00.0	70.0-124.3	90.0	03.0-134.0	
Interval between	28	21-29	34	28-36	42	28-42	***
procedures (d)	20	21-27	54	20-30	74	20-72	



Procedure duration







RBC requirement

	On MET		On ECP				
N = 10			1 st year		2 nd year		P value
	Median	Range	Median	Range	Median	Range	
RBC volume requirement	18.3	15.0-20.0	32.7	26.6-36.1	29.8	23,1-35,3	***
(ml/kg/procedure)	10.5	13.0-20.0	52.7	20.0-50.1	29.0	23.1-33.3	
Packed RBC requirement	39.5	15.0-64.0	74.0	50.0-130.0	60.5	38.0-135.0	**
(units/year)	59.0	13.0-04.0	74.0	50.0-150.0	00.5	38.0-135.0	


15-

10-

5-

0-

MET



RBC requirement/year

#CP NY

#CP 24





Cost evaluation

		On			
	On MET	1st year	2 nd year	P value	
Total cost for packed RBC	50804.04€	88263.24€	78079.02€	N5	
One day clinic cost	24094.98€	29473.47€	25191.00€	N5	
Chelation cost	32193€	22448€	0€	(N5)	
TOTAL COST PER YEAR	107092.02€	140184.71€	103270.02€	NS	





Conclusion

- ECP is a safe and a useful procedure for children with sickle cell disease requiring exchange transfusion program
- ECP is less time consuming and therefore decreases the burden of the disease
- ECP improves iron overload
- Despite the higher cost related to the increased packed RBC requirement, the cost of ECP and MET are equal in the Belgian Health Care System





Next step

- To follow the rate of allo-immunization
- To develop new protocol for children with < 30kg





Acknowledgements

- One day clinic nurses
- Dr A. Ferster
- Dr P-Q. Lê
- Blood Bank
 - H. El Kenz





• All patients and their family



